Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 18 Glioma 11 Neoplasms 6 Brain Neoplasms 6 Astrocytoma 6 Neuroblastoma 4 Sarcoma, Ewing 3 Gliosarcoma 3 Sarcoma 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Medulloblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Wilms Tumor 1 Spinal Cord Neoplasms 1 Rhabdoid Tumor 1 Refractory Solid Tumors 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Metastasis 1 Melanoma, Cutaneous Malignant 1 Melanoma 1 Lymphoma, Follicular 1 Hepatoblastoma 1 Ganglioneuroblastoma 1

Interventions

lutetium Lu 177 dotatate 5 Specimen Handling 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 olaparib 2 fludarabine 2 cabozantinib 2 X-Rays 2 Phantoms, Imaging 2 Cyclophosphamide 2 tivozanib 1 repotrectinib 1 pazopanib 1 fludarabine phosphate 1 entrectinib 1 belinostat 1 atezolizumab 1 aldesleukin 1 Yttrium-90 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Temozolomide 1 Single Photon Emission Computed Tomography Computed Tomography 1 Salts 1 Positron Emission Tomography Computed Tomography 1 PT-100 dipeptide 1 Octreotide 1 Nivolumab 1 Introns 1 Interferon alpha-2 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Temozolomide × 30 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡